Takeda Pharmaceutical Company Limited and Noile-Immune Biotech Inc. have entered into a collaboration to develop next generation chimeric antigen receptor T-cell therapy (CAR-T).

Noile-Immune has exclusive licence for a next generation CAR-T cell therapy developed at Yamaguchi University. The CAR-T therapy produces cytokines, chemokines and other molecules, and is expected to potentially influence or alter the tumor microenvironment of solid tumor tissues.

The two companies intend to use this technology to discover and develop new CAR-T immunotherapies, with the aim of treating a broad range of cancers. In addition to providing resources required for implementation, Takeda will make a technology access payment to Noile-Immune Biotech as well as an equity investment.

Takeda will have exclusive options to obtain licensing rights for the development and commercialization of Noile-Immune’s pipeline and products resulting from this partnership on pre-agreed terms.

Takeda signed the agreement with Noile-Immune through its wholly-owned subsidiary, Millennium Pharmaceuticals, Inc.